News about Drug Discovery & Development

Sun Pharma Launches a Tedizolid Phosphate Tablets in India

STARIZO (Tedizolid Phosphate) is a novel, oxazolidinone-class antibacterial, used to treat Acute Bacterial Skin and Skin Structure Infection (ABSSSI).

Drug Discovery & Development | 26/08/2024 | By Aishwarya |  814

RedHill Biopharma Announces Roll Out of Talicia in UAE

The commercial launch of Talicia in the UAE triggers RedHill's eligibility for additional potential milestone payments, minimum sales payments and tiered royalties up to mid-teens on net sales.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  983

Bridge Biotherapeutics and HitGen to Advance Novel Cancer Therapeutics Program

Bridge plans to strengthen its existing oncology portfolio, which is centered on EGFR inhibitors for lung cancer treatment, through new anticancer drug candidates targeting undisclosed targets.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  474

Clarity Secures FDA Fast Track Designation for 64Cu-SAR-bisPSMA

Clarity Pharmaceuticals has announced that the US Food and Drug Administration (FDA) has granted Fast Track Designation for 64Cu-SAR-bisPSMA for positron emission tomography (PET) imaging of prostate-specific membrane antigen (PSMA) positive prostate cancer lesions.

Drug Discovery & Development | 23/08/2024 | By Aishwarya |  264

Dr. Reddy's, Aurigene and Kainomyx to Jointly Develop Affordable Anti-Malarial Drug

Under the MoU, Kainomyx has agreed to lead the technical strategy and associated aspects for drug discovery and clinical phases, Aurigene has agreed to focus on developing cost-effective and scalable drug chemistry, and while the program evolves, Dr. Reddy’s will bring in its regulatory and market access expertise.

Drug Discovery & Development | 22/08/2024 | By Aishwarya |  453

BerGenBio Partners with Tempus to Accelerate Development in STK11m Non-Small Cell Lung Cancer

BerGenBio's on-going BGBC016 Phase 1b/2a trial is designed to assess the benefit of adding bemcentinib to the current standard of care treatment (immunotherapy + doublet chemotherapy) in 1L STK11m patients, a population with poor outcomes and no specific therapies today.

Drug Discovery & Development | 21/08/2024 | By Aishwarya |  570

Glenmark Therapeutics Unveils Olopatadine Hydrochloride Ophthalmic Solution

Glenmark Therapeutics has launched Olopatadine Hydrochloride Ophthalmic Solution USP, 0.1 percent (OTC) as compared to the active ingredient in Pataday Twice Daily Relief.

Drug Discovery & Development | 20/08/2024 | By Aishwarya |  558

Phanes PT217 Gets Orphan Drug Designation for Neuroendocrine Carcinoma

PT217 is a first-in-class bispecific antibody targeting delta-like ligand 3 (DLL3) and cluster of differentiation 47 (CD47) being developed for patients with NEC.

Drug Discovery & Development | 17/08/2024 | By Aishwarya |  423

Lupin Secures Tentative Approval from FDA for Brimonidine Tartrate Ophthalmic Solution

Lupin has received tentative approval from the United States Food and Drug Administration (U.S. FDA) for its Abbreviated New Drug Application for Brimonidine Tartrate Ophthalmic Solution, 0.025 percent (OTC).

Drug Discovery & Development | 16/08/2024 | By Aishwarya |  858

Citius Pharma Subsidiary Acquires TenX Keane to Establish Citius Oncology

Citius Pharmaceuticals, Inc. has completed the previously announced merger of its oncology subsidiary with TenX Keane Acquisition (TenX).

Drug Discovery & Development | 14/08/2024 | By Aishwarya |  609